Skip to main content

Advertisement

SpringerLink
Log in

Epidemiology and clinical manifestations of cardiac amyloidosis

  • Published:
Heart Failure Reviews Aims and scope Submit manuscript

Abstract

Cardiac amyloidosis, once considered a rare disease, has garnered significant attention over the last few years due to three key reasons: first, increased recognition of this disease in conjunction with various common cardiac conditions such as heart failure with preserved ejection fraction and aortic stenosis; second, due to the advent of promising new therapies for light chain disease (AL), transthyretin (ATTR) cardiomyopathy, and amyloid neuropathy; finally, the advancements in cardiac imaging including echocardiography, magnetic resonance imaging, and nuclear cardiac scintigraphy aid in non-biopsy diagnosis of ATTR cardiac amyloidosis. The hereditary forms of ATTR have further come into importance with the availability of genetic testing and increased prevalence of certain mutations in African Americans. Recognition of non-cardiac clues to this disease has gained importance and reiterates that high clinical suspicion, detailed patient history, and examination with appropriate use of imaging are vital to confirm the diagnosis.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5
Fig. 6

Similar content being viewed by others

References

  1. Sipe JD, Cohen AS (2000) Review: history of the amyloid fibril. J Struc Bio 130(2–3):88–98, ISSN 1047–8477

  2. Kyle RA (2001) Amyloidosis: a convoluted story. Br J Haematol 114(3):529–538. https://doi.org/10.1046/j.1365-2141.2001.02999.x (PMID: 11552976)

    Article  CAS  PubMed  Google Scholar 

  3. Eanes ED, Glenner GG (1968) X-ray diffraction studies on amyloid filaments. J Histochem Cytochem 16(11):673–677. https://doi.org/10.1177/16.11.673 (PMID: 5723775)

    Article  CAS  PubMed  Google Scholar 

  4. Martinez-Naharro A, Hawkins PN, Fontana M (2018) Cardiac amyloidosis. Clin Med (Lond) 18(Suppl 2):s30–s35. https://doi.org/10.7861/clinmedicine.18-2-s30

    Article  Google Scholar 

  5. Sipe JD, Benson MD, Buxbaum JN, Ikeda S, Merlini G, Saraiva MJ, Westermark P (2014) Nomenclature 2014: amyloid fibril proteins and clinical classification of the amyloidosis. Amyloid 21(4):221–224. https://doi.org/10.3109/13506129.2014.964858 (Epub 2014 Sep 29 PMID: 25263598)

    Article  PubMed  Google Scholar 

  6. Shah KB, Inoue Y, Mehra MR (2006) Amyloidosis and the heart: a comprehensive review. Arch Intern Med 166(17):1805–1813. https://doi.org/10.1001/archinte.166.17.1805

    Article  CAS  PubMed  Google Scholar 

  7. González-López E, Gallego-Delgado M, Guzzo-Merello G, de Haro-Del Moral FJ, Cobo-Marcos M, Robles C, Bornstein B, Salas C, Lara-Pezzi E, Alonso-Pulpon L, Garcia-Pavia P (2015) Wild-type transthyretin amyloidosis as a cause of heart failure with preserved ejection fraction. Eur Heart J 36(38):2585–2594. https://doi.org/10.1093/eurheartj/ehv338 (Epub 2015 Jul 28 PMID: 26224076)

    Article  CAS  PubMed  Google Scholar 

  8. Sperry BW, Reyes BA, Ikram A, Donnelly JP, Phelan D, Jaber WA, Shapiro D, Evans PJ, Maschke S, Kilpatrick SE, Tan CD, Rodriguez ER, Monteiro C, Tang WHW, Kelly JW, Seitz WH Jr, Hanna M (2018) Tenosynovial and cardiac amyloidosis in patients undergoing carpal tunnel release. J Am Coll Cardiol 72(17):2040–2050. https://doi.org/10.1016/j.jacc.2018.07.092 (PMID: 30336828)

    Article  PubMed  Google Scholar 

  9. Maurizi N, Rella V, Fumagalli C, Salerno S, Castelletti S, Dagradi F, Torchio M, Marceca A, Meda M, Gasparini M, Boschi B, Girolami F, Parati G, Olivotto I, Crotti L, Cecchi F (2020) Prevalence of cardiac amyloidosis among adult patients referred to tertiary centres with an initial diagnosis of hypertrophic cardiomyopathy. Int J Cardiol 1(300):191–195. https://doi.org/10.1016/j.ijcard.2019.07.051 (Epub 2019 Jul 17 PMID: 31371117)

    Article  Google Scholar 

  10. Rapezzi C, Lorenzini M, Longhi S, Milandri A, Gagliardi C, Bartolomei I, Salvi F, Maurer MS (2015) Cardiac amyloidosis: the great pretender. Heart Fail Rev 20:117–124. https://doi.org/10.1007/s10741-015-9480-0

    Article  CAS  PubMed  Google Scholar 

  11. Gilstrap LG, Dominici F, Wang Y, Samir El-Sady M, Singh A, Di Carli MF, Falk RH, Dorbala S (2019) Epidemiology of cardiac amyloidosis–associated heart failure hospitalizations among fee-for-service Medicare beneficiaries in the United States. Circ Heart Fail 12:e005407. https://doi.org/10.1161/CIRCHEARTFAILURE.118.005407

    Article  PubMed  PubMed Central  Google Scholar 

  12. Rozenbaum MH, Large S, Bhambri R, Stewart M, Whelan J, van Doornewaard A, Dasgupta N, Masri A, Nativi-Nicolau J (2021) Impact of delayed diagnosis and misdiagnosis for patients with transthyretin amyloid cardiomyopathy (ATTR-CM): a targeted literature review. Cardiol Ther 10(1):141–159. https://doi.org/10.1007/s40119-021-00219-5. Epub 2021 Apr 20. PMID: 33877591; PMCID: PMC8126532

  13. Maurer MS, Schwartz JH, Gundapaneni B, Elliott PM, Merlini G, Waddington-Cruz M, Kristen AV, Grogan M, Witteles R, Damy T, Drachman BM, Shah SJ, Hanna M, Judge DP, Barsdorf AI, Huber P, Patterson TA, Riley S, Schumacher J, Stewart M, Sultan MB, Rapezzi C (2018) ATTR-ACT Study Investigators. Tafamidis Treatment for Patients with Transthyretin Amyloid Cardiomyopathy. N Engl J Med 379(11):1007–1016. https://doi.org/10.1056/NEJMoa1805689. Epub 2018 Aug 27. PMID: 30145929

  14. Kittleson MM, Maurer MS, Ambardekar AV, Bullock-Palmer RP, Chang PP, Eisen HJ, Nair AP, Nativi-Nicolau J, Ruberg FL (2020) American Heart Association Heart Failure and Transplantation Committee of the Council on Clinical Cardiology. Cardiac amyloidosis: evolving diagnosis and management: a scientific statement from the American Heart Association. Circulation 142(1):e7-e22. https://doi.org/10.1161/CIR.0000000000000792. Epub 2020 Jun 1. PMID: 32476490

  15. Dittrich T, Kimmich C, Hegenbart U, Schönland SO (2020) Prognosis and staging of AL amyloidosis. Acta Haematol 143(4):388–400. https://doi.org/10.1159/000508287 (Epub 2020 Jun 22 PMID: 32570242)

    Article  CAS  PubMed  Google Scholar 

  16. Falk RH, Alexander KM, Liao R, Dorbala S (2016) AL (light-chain) cardiac amyloidosis: a review of diagnosis and therapy. J Am Coll

  17. Hasserjian RP, Goodman HJ, Lachmann HJ et al (2007) Bone marrow findings correlate with clinical outcome in systemic AL amyloidosis patients. Histopathology 50:567–573

    Article  CAS  Google Scholar 

  18. Shi J, Guan J, Jiang B, Brenner DA, Del Monte F, Ward JE, Connors LH, Sawyer DB, Semigran MJ, Macgillivray TE, Seldin DC, Falk R, Liao R (2010) Amyloidogenic light chains induce cardiomyocyte contractile dysfunction and apoptosis via a non-canonical p38alpha MAPK pathway. Proc Natl Acad Sci USA 107(9):4188–93. https://doi.org/10.1073/pnas.0912263107. Epub 2010 Feb 11. PMID: 20150510; PMCID: PMC2840082

  19. Quarta CC, Kruger JL, Falk RH (2012) Cardiac amyloidosis. Circulation 126(12):e178–e182. https://doi.org/10.1161/CIRCULATIONAHA.111.069195 (PMID: 22988049)

    Article  PubMed  Google Scholar 

  20. Mayo Clinic Proceedings (2019) 93(3):465–71

  21. Gertz MA (2016) Immunoglobulin light chain amyloidosis: 2016 update on diagnosis, prognosis, and treatment. Am J Hematol 91(9):947–956. https://doi.org/10.1002/ajh.24433 (PMID: 27527836)

    Article  CAS  PubMed  Google Scholar 

  22. Grogan M, Dispenzieri A, Gertz MA (2017) Light-chain cardiac amyloidosis: strategies to promote early diagnosis and cardiac response. Heart 103(14):1065–1072. https://doi.org/10.1136/heartjnl-2016-310704. Epub 2017 Apr 29. PMID: 28456755; PMCID: PMC5566095

  23. Kumar S, Dispenzieri A, Lacy MQ, Hayman SR, Buadi FK, Colby C, Laumann K, Zeldenrust SR, Leung N, Dingli D, Greipp PR, Lust JA, Russell SJ, Kyle RA, Rajkumar SV, Gertz MA (2012) Revised prognostic staging system for light chain amyloidosis incorporating cardiac biomarkers and serum free light chain measurements. J Clin Oncol 30(9):989–95. https://doi.org/10.1200/JCO.2011.38.5724. Epub 2012 Feb 13. PMID: 22331953; PMCID: PMC3675680

  24. Buxbaum JN, Chuba JV, Hellman GC, Solomon A, Gallo GR (1990) Monoclonal immunoglobulin deposition disease: light chain and light and heavy chain deposition diseases and their relation to light chain amyloidosis. Clinical features, immunopathology, and molecular analysis. Ann Intern Med 112(6):455–64. https://doi.org/10.7326/0003-4819-76-3-112-6-455. PMID: 2106817

  25. Dispenzieri A (2021) Clinical presentation, laboratory manifestations, and diagnosis of immunoglobulin light chain (AL) amyloidosis In: UpToDate, Post TW (Ed), UpToDate, Waltham, MA. (Accessed on May 16, 2021)

  26. Desport E, Bridoux F, Sirac C et al (2012) Al amyloidosis. Orphanet J Rare Dis 2012;7:54. Published 2012 Aug 21. https://doi.org/10.1186/1750-1172-7-54

  27. Baker KR, Rice L (2012) The amyloidoses: clinical features, diagnosis and treatment. Methodist Debakey Cardiovasc J 8(3):3–7. https://doi.org/10.14797/mdcj-8-3-3

    Article  PubMed  PubMed Central  Google Scholar 

  28. Selvanayagam JB, Hawkins PN, Paul B, Myerson SG, Neubauer S (2007) Evaluation and management of the cardiac amyloidosis. J Am Coll Cardiol 207(50):2101–2110

    Article  Google Scholar 

  29. Kappor P, Thenappan T, Singh E, Kumar S, Greipp PR (2011) Cardiac amyloidosis: a practical approach to diagnosis and management. Am J Med 124:1006–1015. https://doi.org/10.1016/j.amjmed.2011.04.013

    Article  CAS  Google Scholar 

  30. Rajkumar SV, Dimopoulos MA, Palumbo A et al (2014) International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma. Lancet Oncol 15:e538

  31. Dorbala S, Cuddy S, Falk RH (2020) How to image cardiac amyloidosis: a practical approach. JACC Cardiovasc Imaging 13(6):1368–1383. https://doi.org/10.1016/j.jcmg.2019.07.015. Epub 2019 Oct 11. PMID: 31607664; PMCID: PMC7148180

  32. Kapoor P, Thenappan T, Singh E, Kumar S, Greipp PR (2011) Cardiac amyloidosis: a practical approach to diagnosis and management. Am J Med 124(11):1006–1015. https://doi.org/10.1016/j.amjmed.2011.04.013 (PMID: 22017778)

    Article  CAS  PubMed  Google Scholar 

  33. Maurer MS, Hanna M, Grogan M, Dispenzieri A, Witteles R, Drachman B, Judge DP, Lenihan DJ, Gottlieb SS, Shah SJ, Steidley DE, Ventura H, Murali S, Silver MA, Jacoby D, Fedson S, Hummel SL, Kristen AV, Damy T, Planté-Bordeneuve V, Coelho T, Mundayat R, Suhr OB, Waddington Cruz M, Rapezzi C (2016) THAOS Investigators. Genotype and phenotype of transthyretin cardiac amyloidosis: THAOS (Transthyretin Amyloid Outcome Survey). J Am Coll Cardiol 68(2):161–72. https://doi.org/10.1016/j.jacc.2016.03.596. PMID: 27386769; PMCID: PMC4940135

  34. Ruberg FL, Grogan M, Hanna M, Kelly JW, Maurer MS (2019) Transthyretin amyloid cardiomyopathy: JACC state-of-the-art review. J Am Coll Cardiol 73(22):2872–2891. https://doi.org/10.1016/j.jacc.2019.04.003.PMID:31171094;PMCID:PMC6724183

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  35. Maurer MS, Bokhari S, Damy T, Dorbala S, Drachman BM, Fontana M, Grogan M, Kristen AV, Lousada I, Nativi-Nicolau J, Cristina Quarta C, Rapezzi C, Ruberg FL, Witteles R, Merlini G (2019) Expert consensus recommendations for the suspicion and diagnosis of transthyretin cardiac amyloidosis. Circ Heart Fail 12(9):e006075. https://doi.org/10.1161/CIRCHEARTFAILURE.119.006075. Epub 2019 Sep 4. PMID: 31480867; PMCID: PMC6736650

  36. Jacobson DR, Pastore R, Pool S, Malendowicz S, Kane I, Shivji A, Embury SH, Ballas SK, Buxbaum JN (1996) Revised transthyretin Ile 122 allele frequency in African-Americans.Hum Genet 98:236–238. https://doi.org/10.1007/s004390050199

  37. Quarta CC, Buxbaum JN, Shah AM, Falk RH, Claggett B, Kitzman DW, Mosley TH, Butler KR, Boerwinkle E, Solomon SD (2015) The amyloidogenic V122I transthyretin variant in elderly black Americans. N Engl J Med 372:21–29. https://doi.org/10.1056/NEJMoa1404852

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  38. Gorevic PD, Prelli FC, Wright J, Pras M, Frangione B (1989) Systemic senile amyloidosis. Identification of a new prealbumin (transthyretin) variant in cardiac tissue: immunologic and biochemical similarity to one form of familial amyloidotic polyneuropathy. J Clin Invest 83:836–843

  39. Pomerance A (1965) Senile cardiac amyloidosis. Br Heart J 27(5):711–718. https://doi.org/10.1136/hrt.27.5.711.PMID:5829755;PMCID:PMC469777

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  40. Manso MC, Marques DP, Rocha SL, Rodeia SC, Domingos R (2017) Senile Systemic Amyloidosis: An Underdiagnosed Disease. Eur J Case Rep Intern Med 4(9):000725. https://doi.org/10.12890/2017_000725 (PMID:30755970;PMCID:PMC6346851)

    Article  PubMed  PubMed Central  Google Scholar 

  41. Pitkänen P, Westermark P, Cornwell GG 3rd (1984) Senile systemic amyloidosis. Am J Pathol 117(3):391–9. PMID: 6507586; PMCID: PMC1900583

  42. Bonaïti B, Olsson M, Hellman U, Suhr O, Bonaïti-Pellié C, Planté-Bordeneuve V (2010) TTR familial amyloid polyneuropathy: does a mitochondrial polymorphism entirely explain the parent-of-origin difference in penetrance? Eur J Hum Genet 18(8):948–52. https://doi.org/10.1038/ejhg.2010.36. Epub 2010 Mar 17. PMID: 20234390; PMCID: PMC2987385

  43. Rapezzi C, Riva L, Quarta CC, Perugini E, Salvi F, Longhi S, Ciliberti P, Pastorelli F, Biagini E, Leone O, Cooke RM, Bacchi-Reggiani L, Ferlini A, Cavo M, Merlini G, Perlini S, Pasquali S, Branzi A (2008) Gender-related risk of myocardial involvement in systemic amyloidosis. Amyloid 15(1):40–48. https://doi.org/10.1080/13506120701815373 (PMID: 18266120)

    Article  CAS  PubMed  Google Scholar 

  44. Suhr OB, Lindqvist P, Olofsson BO, Waldenström A, Backman C (2006) Myocardial hypertrophy and function are related to age at onset in familial amyloidotic polyneuropathy. Amyloid 13(3):154–159. https://doi.org/10.1080/13506120600876849 (PMID: 17062381)

    Article  PubMed  Google Scholar 

  45. Ng B, Connors LH, Davidoff R, Skinner M, Falk RH (2005) Senile systemic amyloidosis presenting with heart failure: A comparison with light chain-associated amyloidosis. Arch Intern Med 165:1425–1429

    Article  Google Scholar 

  46. Kapoor M, Rossor AM, Laura M, Reilly MM (2019) Clinical Presentation, Diagnosis and Treatment of TTR Amyloidosis. J Neuromuscul Dis 6(2):189–199. https://doi.org/10.3233/JND-180371

    Article  PubMed  PubMed Central  Google Scholar 

  47. Sekijima Y, Ueda M, Koike H, Misawa S, Ishii T, Ando Y (2018) Diagnosis and management of transthyretin familial amyloid polyneuropathy in Japan: Red-flag symptom clusters and treatment algorithm. Orphanet J Rare Dis 13(1):6. https://doi.org/10.1186/s13023-017-0726-x

    Article  PubMed  PubMed Central  Google Scholar 

  48. Michels da Silva D, Langer H, Graf T (2019) Inflammatory and Molecular Pathways in Heart Failure-Ischemia, HFpEF and Transthyretin Cardiac Amyloidosis. Int J Mol Sci 20(9):2322. Published 2019 May 10. https://doi.org/10.3390/ijms20092322

  49. Conceição I, González-Duarte A, Obici L, Schmidt HH, Simoneau D, Ong ML, Amass L (2016) “Red-flag” symptom clusters in transthyretin familial amyloid polyneuropathy. J Peripher Nerv Syst 21(1):5–9. https://doi.org/10.1111/jns.12153 (PMID:26663427;PMCID:PMC4788142)

    Article  PubMed  PubMed Central  Google Scholar 

  50. Gertz MA, Dispenzieri A (2020) Systemic Amyloidosis Recognition, Prognosis, and Therapy: A Systematic Review. JAMA 324(1):79–89. https://doi.org/10.1001/jama.2020.5493

    Article  CAS  PubMed  Google Scholar 

  51. Ponikowski P, Voors AA, Anker SD, Bueno H, Cleland JGF et al (2016) 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: the Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC) Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur Heart J 37:2129–2200

    Article  Google Scholar 

  52. Caruana L, Petrie MC, Davie AP, McMurray JJ (2000) Do patients with suspected heart failure and preserved left ventricular systolic function suffer from “diastolic heart failure” or from misdiagnosis? A prospective descriptive study. BMJ 321(7255):215–218. https://doi.org/10.1136/bmj.321.7255.215 (PMID:10903655;PMCID:PMC27439)

    Article  CAS  PubMed  Google Scholar 

  53. González-López E, Gallego-Delgado M, Guzzo-Merello G, de Haro-del Moral FJ, Cobo-Marcos M et al (2015) Wild-type transthyretin amyloidosis as a cause of heart failure with preserved ejection fraction. Euro Heart J 36(38):2585–2594

  54. Castaño A, Narotsky DL, Hamid N, Khalique OK, Morgenstern R et al (2017) Unveiling transthyretin cardiac amyloidosis and its predictors among elderly patients with severe aortic stenosis undergoing transcatheter aortic valve replacement. Eur Heart J 38(38):2879–2887. https://doi.org/10.1093/eurheartj/ehx350 (PMID:29019612;PMCID:PMC5837725)

    Article  PubMed  PubMed Central  Google Scholar 

  55. Grogan M, Scott CG, Kyle RA, Zeldenrust SR, Gertz MA, Lin G et al (2016) A Natural History of Wild-Type Transthyretin Cardiac Amyloidosis and Risk Stratification Using a Novel Staging System. J Am Coll Cardiol 68(10):1014–20. https://doi.org/10.1016/j.jacc.2016.06.033. Erratum in: J Am Coll Cardiol. 2017 Jun 13;69(23):2882. PMID: 27585505

  56. Driggin E, Maurer MS (2020) The quintessential form of diastolic heart failure in older adults: Wild type transthyretin cardiac amyloidosis. Clin Cardiol 43(2):171–178. https://doi.org/10.1002/clc.23301. Epub 2019 Dec 11. PMID: 31825134; PMCID: PMC7021652

  57. Galat A, Guellich A, Bodez D, Slama M, Dijos M et al (2016) Aortic stenosis and transthyretin cardiac amyloidosis: the chicken or the egg? Eur Heart J 37(47):3525–3531

    Article  Google Scholar 

  58. Longhi S, Lorenzini M, Gagliardi C, Milandri A, Marzocchi A (2016) Coexistence of Degenerative Aortic Stenosis and Wild-Type Transthyretin-Related Cardiac Amyloidosis, JACC: Cardiovasc Imag 9(3):325–327, ISSN 1936–878X. https://doi.org/10.1016/j.jcmg.2015.04.012

  59. Ternacle J, Krapf L, Mohty D, Magne J, Nguyen A et al (2019) Aortic Stenosis and Cardiac Amyloidosis: JACC Review Topic of the Week. J Am Coll Cardiol 74(21):2638–2651. https://doi.org/10.1016/j.jacc.2019.09.056 (PMID: 31753206)

    Article  PubMed  Google Scholar 

  60. Gaffney PM (2017) Amyloid A Amyloidosis. Vet Pathol 54(1):5–8. https://doi.org/10.1177/0300985816677150. Epub 2016 Nov 24. PMID: 27879441.42

  61. Uhlar CM, Whitehead AS (1999) Serum amyloid A, the major vertebrate acute-phase reactant. Eur J Biochem 265(2):501–523

    Article  CAS  Google Scholar 

  62. Obici L, Raimondi S, Lavatelli F, Bellotti V, Merlini G (2009) Susceptibility to AA amyloidosis in rheumatic diseases: a critical overview. Arthritis Rheum 61(10):1435–1440

    Article  CAS  Google Scholar 

  63. Papa R, Lachmann HJ (2018) Secondary, AA, Amyloidosis. Rheum Dis Clin North Am 44(4):585–603. https://doi.org/10.1016/j.rdc.2018.06.004 (Epub 2018 Sep 7 PMID: 30274625)

    Article  PubMed  Google Scholar 

  64. Okuda Y, Yamada T, Ueda M, Ando Y (2018) First Nationwide Survey of 199 Patients with Amyloid A Amyloidosis in Japan. Intern Med 57(23):3351–3355. https://doi.org/10.2169/internalmedicine.1099-18. Epub 2018 Aug 10. PMID: 30101921; PMCID: PMC6306533

  65. Steiner I, Hájková P (2006) Patterns of isolated atrial amyloid: a study of 100 hearts on autopsy. Cardiovasc Pathol 15(5):287–290. https://doi.org/10.1016/j.carpath.2006.01.005. PMID: 16979036

  66. Steiner I (1987) The prevalence of isolated atrial amyloid. J Pathol 153(4):395–398. https://doi.org/10.1002/path.1711530413 (PMID: 3430237)

    Article  CAS  PubMed  Google Scholar 

  67. Röcken C, Peters B, Juenemann G, Saeger W, Klein HU, Huth C, Roessner A, Goette A (2002) Atrial amyloidosis: an arrhythmogenic substrate for persistent atrial fibrillation. Circulation 106(16):2091–2097. https://doi.org/10.1161/01.cir.0000034511.06350.df (PMID: 12379579)

    Article  PubMed  Google Scholar 

  68. Podduturi V, Armstrong DR, Hitchcock MA, Roberts WC, Guileyardo JM (2013) Isolated atrial amyloidosis and the importance of molecular classification. Proc (Bayl Univ Med Cent) 26(4):387–389. https://doi.org/10.1080/08998280.2013.11929013 (PMID:24082415;PMCID:PMC3777087)

    Article  Google Scholar 

  69. Sukhacheva TV, Eremeeva MV, Ibragimova AG, Vaskovskii VA, Serov RA, Revishvili ASh (2016) Isolated atrial amyloidosis in patients with various types of atrial fibrillation. Bull Exp Biol Med 160(6):844–849. https://doi.org/10.1007/s10517-016-3324-3 (Epub 2016 May 10 PMID: 27160887)

    Article  CAS  PubMed  Google Scholar 

  70. Krishnappa D, Dykoski R, Can I, Mbai M, Anand IS, Florea V, Chandrashekar YS, Li JM, Tholakanahalli VN (2019) Atrial fibrillation in the elderly: The role of sub-clinical isolated cardiac amyloidosis. Sci Rep 9(1):16584. https://doi.org/10.1038/s41598-019-53119-z (PMID:31719596;PMCID:PMC6851153)

    Article  PubMed  PubMed Central  Google Scholar 

  71. Bois MC, Dasari S, Mills JR, Theis J, Highsmith WE, Vrana JA, Grogan M, Dispenzieri A, Kurtin PJ, Maleszewski JJ (2017) Apolipoprotein A-IV-Associated cardiac amyloidosis. J Am Coll Cardiol 69(17):2248–2249. https://doi.org/10.1016/j.jacc.2017.02.047 (PMID: 28449784)

    Article  PubMed  Google Scholar 

  72. Miyazaki S, Kadota A, Mitsui I, Murakami T (2020) Amyloid Signature Proteins in Feline Amyloidosis. J Comp Pathol 177:10–17. https://doi.org/10.1016/j.jcpa.2020.03.007 (Epub 2020 Apr 23 PMID: 32505236)

    Article  CAS  PubMed  Google Scholar 

  73. Lu C, Zuo K, Lu Y, Liang S, Huang X, Zeng C, Zhang J, An Y, Wang J (2017) Apolipoprotein A-1-related amyloidosis 2 case reports and review of the literature. Medicine (Baltimore) 96(39):e8148. https://doi.org/10.1097/MD.0000000000008148 (PMID:28953655;PMCID:PMC5626298)

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Cardiology, University of Rochester Medical Center, Rochester, NY, USA

    Farhan Bajwa & Ryan O’Connor

  2. Henry Ford West Bloomfield Hospital, Heart and Vascular Institute, West Bloomfield, MI, 48322, USA

    Karthikeyan Ananthasubramaniam

Authors
  1. Farhan Bajwa
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Ryan O’Connor
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Karthikeyan Ananthasubramaniam
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Karthikeyan Ananthasubramaniam.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Bajwa, F., O’Connor, R. & Ananthasubramaniam, K. Epidemiology and clinical manifestations of cardiac amyloidosis. Heart Fail Rev 27, 1471–1484 (2022). https://doi.org/10.1007/s10741-021-10162-1

Download citation

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10741-021-10162-1

Keywords

Search

Navigation